Grants per year
Personal profile
Research Interests
Personalized Cancer Therapy, Precision Medicine, Early Phase Clinical Trials, First-in-Human Study, Novel Combination Cancer Therapy, Targeted therapy, Immunotherapy, Biomarker Study, Novel Drug Development, Novel Drug Delivery System, Adaptive Clinical Trials Design, Cell Signaling Pathway, Immune Checkpoint Pathway
Training Experience
| 2011 | Residency, Albert Einstein Medical Center |
| 2014 | Fellowship, University of Texas/MD Anderson Cancer Center |
Education/Academic qualification
MBA, Johns Hopkins University
… → 2007
MPH, Johns Hopkins University
… → 2007
MD, Seoul National University
… → 2002
Research interests
- Oncology
Fingerprint
Dive into the research topics where Young Kwang Chae is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 7 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Grants
-
Prot #RMC-4630-02: A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 with Cobimetinib in Adult Participants with Relapsed/Refractory Solid Tumors and a Phase 1b Study of RMC-4630 with Osimertinib
PPD Investigator Services, LLC, Revolution Medicines, Inc.
7/7/20 → 7/7/23
Project: Research project
-
The distinct role of cysteinyl leukotriene receptor for myeloid-derived suppressive cells
Chae, Y. K., Fang, D., Sosman, J. A., Zhang, B. & Zou, L.
5/15/20 → 4/30/25
Project: Research project
Research Output
-
The Impact of Beta Blockers on Survival Outcomes in Patients With Non–small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Oh, M. S., Guzner, A., Wainwright, D. A., Mohindra, N. A., Chae, Y. K., Behdad, A. & Villaflor, V. M., Jan 2021, In: Clinical Lung Cancer. 22, 1, p. e57-e62Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors
Patel, S. P., Othus, M., Chae, Y. K., Giles, F. J., Hansel, D. E., Singh, P. P., Fontaine, A., Shah, M. H., Kasi, A., Baghdadi, T. A., Matrana, M., Gatalica, Z., Korn, W. M., Hayward, J., McLeod, C., Chen, H. X., Sharon, E., Mayerson, E., Ryan, C. W., Plets, M. & 2 others, , May 15 2020, In: Clinical Cancer Research. 26, 10, p. 2290-2296 7 p.Research output: Contribution to journal › Article › peer-review
Open Access23 Scopus citations -
Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer
Park, W., Mezquita, L., Okabe, N., Chae, Y. K., Kwon, D., Saravia, D., Auclin, E., Planchard, D., Caramella, C., Ferrara, R., Agte, S., Oh, M., Mudad, R., Jahanzeb, M., Suzuki, H., Besse, B. & Lopes, G., Feb 4 2020, In: British Journal of Cancer. 122, 3, p. 340-347 8 p.Research output: Contribution to journal › Article › peer-review
4 Scopus citations -
Early Assessment of Molecular Progression and Response by Whole-genome Circulating Tumor DNA in Advanced Solid Tumors
Davis, A. A., Iams, W. T., Chan, D., Oh, M. S., Lentz, R. W., Peterman, N., Robertson, A., Shah, A., Srivas, R., Wilson, T. J., Lambert, N. J., George, P. S., Wong, B., Wood, H. W., Close, J. C., Tezcan, A., Nesmith, K., Tezcan, H. & Chae, Y. K., Jul 1 2020, In: Molecular cancer therapeutics. 19, 7, p. 1486-1496 11 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
trial investigators, Feb 2020, In: The Lancet Oncology. 21, 2, p. 271-282 12 p.Research output: Contribution to journal › Article › peer-review
118 Scopus citations